HC Wainwright set a $12.00 price objective on DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) in a research note released on Monday, October 16th. The firm currently has a buy rating on the stock.
“Ovarian Cancer Role for VAL-083; Reiterate Buy Stock Data 10/13/2017 Price $0.88 Exchange NASDAQ Price Target $12.00 52-Week High $5.77 52-Week Low $0.80 Enterprise Value (M) $12.4 Market Cap (M) $19 Public Market Float (M) 19.3 Shares Outstanding (M) 21.6 3 Month Avg Volume 959,521 Short Interest (M) 0.35 Balance Sheet Metrics Cash (M) $6.59 Total Debt (M) $0.00 Total Cash/Share $0.31 Book Value/Share $(0.09) EPS Diluted Full Year – Jun 2016A 2017A 2018E 1Q (0.15) (0.23) (0.17) 2Q (0.24) (0.13) (0.16) 3Q (0.10) (0.18) (0.14) 4Q (0.31) (0.20) (0.12) FY (0.81) (0.74) (0.57) 6 5 4 3 2 1 0 OCT- 16 FEB- 17 J UN- 17 OCT- 17 40 30 20 10 0 Vol. (mil) Price Continuing coverage under the name H.C. Wainwright & Co. with a Buy rating. Effective October 5, 2017, research in the above titled name will now be published under H.C. Wainwright & Co. and no longer distributed in conjunction with ‘Rodman & Renshaw, a unit of H.C.”,” HC Wainwright’s analyst wrote.
A number of other research analysts have also weighed in on the company. Maxim Group restated a hold rating on shares of DelMar Pharmaceuticals in a research report on Monday, September 11th. Dawson James reiterated a buy rating on shares of DelMar Pharmaceuticals in a research report on Tuesday, August 8th.
Shares of DelMar Pharmaceuticals (NASDAQ DMPI) opened at 0.85 on Monday. DelMar Pharmaceuticals has a 12 month low of $0.80 and a 12 month high of $5.39. The company’s market capitalization is $18.32 million. The company’s 50 day moving average price is $0.98 and its 200 day moving average price is $1.83.
ILLEGAL ACTIVITY NOTICE: This article was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2017/10/27/delmar-pharmaceuticals-inc-dmpi-pt-set-at-12-00-by-hc-wainwright.html.
A hedge fund recently bought a new stake in DelMar Pharmaceuticals stock. Sabby Management LLC purchased a new stake in shares of DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 645,390 shares of the company’s stock, valued at approximately $1,484,000. Sabby Management LLC owned approximately 4.79% of DelMar Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 8.64% of the company’s stock.
DelMar Pharmaceuticals Company Profile
DelMar Pharmaceuticals, Inc is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer.
Receive News & Ratings for DelMar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.